한글목차

당뇨병성 족부궤양(DFU)용 생물제제 세계 시장 규모는 2024년 6억 5,000만 달러에서 2030년에는 8억 8,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 5.41%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

DFU는 높은 유병률과 종종 동반되는 합병증으로 인해 전 세계 의료 시스템에 큰 부담을 주고 있습니다. 이러한 궤양은 일반적으로 순환 장애, 신경 장애 및 면역 반응 저하로 인해 발생하기 때문에 기존의 방법으로는 치료가 특히 어렵습니다.

성장인자, 유전자치료, 세포치료와 같은 생물학적 치료는 상처 치유를 촉진하고 감염 위험을 최소화하며 추가 합병증을 줄일 수 있는 능력으로 인해 점점 더 많이 채택되고 있습니다. 이 시장에는 다혈소판 혈장(PRP), 대체 피부, 줄기세포 치료, 유전자 재조합 인간성장인자 등 다양한 생물학적 제제 포트폴리오가 있습니다. 이러한 치료는 조직 재생을 촉진하고, 치유를 촉진하며, 절단과 같은 침습적 치료에 대한 의존도를 줄이는 것을 목표로 합니다.

의료진이 DFU 관리에서 생물학적 제제의 임상적 이점을 지속적으로 인식하고 있기 때문에 이러한 치료에 대한 수요는 지속적으로 증가할 것으로 예상됩니다. 그러나 생물학적 제제의 보급을 가로막는 주요 요인 중 하나는 생물학적 제제 치료에 따른 높은 비용입니다. 이러한 치료제는 고도의 제조 공정과 복잡한 전달 시스템을 필요로 하는 경우가 많으며, 이는 높은 가격의 한 요인이 되고 있습니다. 이는 한정된 예산으로 운영되는 의료진과 환자들에게 큰 도전이 되고 있습니다.

주요 시장 성장 촉진요인

헬스케어 분야 확대

주요 시장 이슈

치료비 폭등

주요 시장 동향

세계 당뇨병 유병률 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 당뇨병성 족부궤양(DFU)용 생물제제 시장에 미치는 영향

제5장 세계의 당뇨병성 족부궤양(DFU)용 생물제제 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 적응증별(신경허혈성 궤양, 신경장애성 당뇨병성 족부궤양, 허혈성 당뇨병성 족부궤양)
  • 최종사용자별(병원, 진료소, 외래수술센터(ASC), 장기요양시설, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 당뇨병성 족부궤양(DFU)용 생물제제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 당뇨병성 족부궤양(DFU)용 생물제제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 당뇨병성 족부궤양(DFU)용 생물제제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 당뇨병성 족부궤양(DFU)용 생물제제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 당뇨병성 족부궤양(DFU)용 생물제제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 출시
• 최근 동향

제13장 세계의 당뇨병성 족부궤양(DFU)용 생물제제 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Organogenesis Inc.
• Tissue Regenix Group Plc
• BioTissue Holdings, Inc.
• Integra LifeSciences Holdings Corporation
• MIMEDX Group, Inc.
• Convatec Inc.
• Smith & Nephew PLC
• Stedical Scientific, Inc.
• Zimmer Biomet Holdings, Inc.
• GUNZE LIMITED

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

영문목차

Global Diabetic foot ulcer (DFU) biologics market was valued at USD 0.65 billion in 2024 and is projected to reach USD 0.88 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.41% during the forecast period. DFUs pose a significant burden on healthcare systems worldwide, driven by their high prevalence and the complications they often entail. These ulcers typically result from impaired circulation, neuropathy, and weakened immune response, making them particularly challenging to treat through conventional methods.

Biologic therapies-such as growth factors, gene therapies, and cellular treatments-are increasingly being adopted for their ability to enhance wound healing, minimize infection risks, and mitigate further complications. The market features a diverse portfolio of biologic products, including platelet-rich plasma (PRP), skin substitutes, stem cell therapies, and recombinant human growth factors. These treatments aim to stimulate tissue regeneration, accelerate healing, and reduce the reliance on invasive interventions, such as amputation.

As medical professionals continue to recognize the clinical benefits of biologics in DFU management, the demand for these therapies is anticipated to grow consistently. However, one of the primary obstacles to broader adoption is the high cost associated with biologic treatments. These therapies often require sophisticated manufacturing processes and complex delivery systems, contributing to their elevated pricing. This presents a significant challenge for healthcare providers and patients operating within constrained budgets.

Key Market Drivers

Expansion of the Healthcare Sector

The rising global incidence of diabetes is a major driver of DFU prevalence, with approximately 15% of diabetic patients developing foot ulcers. Currently, the global prevalence of DFUs among adults with diabetes is estimated at 6.3%, with annual incidence rates ranging from 9.1 to 26.1 million cases. Risk factors include long-standing diabetes, poor glycemic control, peripheral neuropathy, and foot abnormalities such as calluses or deformities.

This growing patient population necessitates more effective treatment modalities, including biologics. Ongoing investment in healthcare research and technological innovation is accelerating the development of novel biologic therapies, improving clinical outcomes and enhancing market growth. Notably, AI-powered diagnostic tools and applications are increasingly used to support the detection and management of DFUs, further improving efficiency and treatment precision.

Key Market Challenges

High Cost of Treatment

Biologic therapies are derived from living organisms and involve highly regulated, intricate manufacturing processes, including cell cultivation, purification of biologically active substances, and development of engineered tissues. These processes often require specialized infrastructure, advanced equipment, and stringent quality assurance protocols, all of which contribute to increased production costs.

Additionally, the research and development (R&D) required to bring biologic products to market is both time-intensive and capital-intensive. Companies must conduct comprehensive preclinical studies and clinical trials to validate product safety and efficacy, as well as navigate complex regulatory pathways. These high development costs are ultimately reflected in the pricing of biologic treatments, posing financial challenges for both healthcare systems and patients.

Key Market Trends

Rising Global Diabetes Prevalence

The incidence of diabetes has increased dramatically over recent decades, particularly in low- and middle-income countries where healthcare access remains limited. The global diabetic population surged from 200 million in 1990 to 830 million by 2022. In 2021 alone, diabetes and its related complications-including kidney disease-accounted for over 2 million deaths. Elevated blood glucose levels were also responsible for approximately 11% of all cardiovascular-related fatalities.

This rising prevalence has directly contributed to an increase in DFU cases, creating greater demand for effective, advanced treatment solutions such as biologics. The DFU biologics market is witnessing robust growth, driven by increasing disease incidence and the expanding availability of innovative therapies. Biologic treatments, particularly those utilizing growth factors and cell-based therapies, are gaining widespread adoption due to their superior efficacy in wound healing and infection control.

Key Market Players

• Organogenesis Inc.
• Tissue Regenix Group Plc
• BioTissue Holdings, Inc.
• Integra LifeSciences Holdings Corporation
• MIMEDX Group, Inc.
• Convatec Inc.
• Smith & Nephew PLC
• Stedical Scientific, Inc.
• Zimmer Biomet Holdings, Inc.
• GUNZE LIMITED

Report Scope

In this report, the Global Diabetic Foot Ulcer Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Foot Ulcer Biologics Market, By Indication:

• Neuro-ischemic Ulcers
• Neuropathic Diabetic Foot Ulcer
• Ischemic Diabetic Foot Ulcer

Diabetic Foot Ulcer Biologics Market, By End User:

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Long-Term Care Settings
• Others

Diabetic Foot Ulcer Biologics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Foot Ulcer Biologics Market.

Available Customizations:

Global Diabetic Foot Ulcer Biologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Diabetic Foot Ulcer Biologics Market

5. Global Diabetic Foot Ulcer Biologics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Neuro-ischemic Ulcers, Neuropathic Diabetic Foot Ulcer, Ischemic Diabetic Foot Ulcer)
  • 5.2.2. By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Long-Term Care Settings, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Diabetic Foot Ulcer Biologics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Diabetic Foot Ulcer Biologics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By End User
  • 6.3.2. Mexico Diabetic Foot Ulcer Biologics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By End User
  • 6.3.3. Canada Diabetic Foot Ulcer Biologics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By End User

7. Europe Diabetic Foot Ulcer Biologics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Diabetic Foot Ulcer Biologics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By End User
  • 7.3.2. Germany Diabetic Foot Ulcer Biologics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom Diabetic Foot Ulcer Biologics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Diabetic Foot Ulcer Biologics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Diabetic Foot Ulcer Biologics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By End User

8. Asia Pacific Diabetic Foot Ulcer Biologics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Diabetic Foot Ulcer Biologics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By End User
  • 8.3.2. India Diabetic Foot Ulcer Biologics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By End User
  • 8.3.3. South Korea Diabetic Foot Ulcer Biologics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By End User
  • 8.3.4. Japan Diabetic Foot Ulcer Biologics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Diabetic Foot Ulcer Biologics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By End User

9. South America Diabetic Foot Ulcer Biologics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Diabetic Foot Ulcer Biologics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Diabetic Foot Ulcer Biologics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Diabetic Foot Ulcer Biologics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By End User

10. Middle East and Africa Diabetic Foot Ulcer Biologics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Diabetic Foot Ulcer Biologics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Diabetic Foot Ulcer Biologics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Diabetic Foot Ulcer Biologics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Diabetic Foot Ulcer Biologics Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Organogenesis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Tissue Regenix Group Plc
• 15.3. BioTissue Holdings, Inc.
• 15.4. Integra LifeSciences Holdings Corporation
• 15.5. MIMEDX Group, Inc.
• 15.6. Convatec Inc.
• 15.7. Smith & Nephew PLC
• 15.8. Stedical Scientific, Inc.
• 15.9. Zimmer Biomet Holdings, Inc.
• 15.10. GUNZE LIMITED

16. Strategic Recommendations

17. About Us & Disclaimer